James Del Rosso, DO: Discussing Early Immune Activity Upon Ruxolitinib Cream Withdrawal
Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster presented findings from the TRuE-V long-term extension (LTE) study, which evaluated changes in serum biomarkers in patients with segmental vitiligo who were randomized in the LTE to apply the vehicle or continue using ruxolitinib 1.5% cream after both groups had used ruxolitinib cream in the parent studies.
Nada Elbuluk, MD: Connecting Patients with Vitiligo with Supportive Resources
Dr. Elbuluk discusses the importance of connecting patients with vitiligo to supportive resources for preventing and mitigating anxiety and depression related to the condition, especially socioeconomically disadvantaged patients who may not be aware of these resources in their community.
Nada Elbuluk, MD: New Research on Psychological Comorbidities in Patients with Vitiligo
Dr. Elbuluk discusses a recently published retrospective chart review that she and her colleagues published in the Archives of Dermatological Research, which included all patients diagnosed with vitiligo treated at a private hospital and a public hospital over a period of ten years, with a focus on associated psychiatric comorbidities. She summarizes the findings of rates of anxiety and depression in patients with vitiligo in terms of gender, race, and socioeconomic status.